| Literature DB >> 35923717 |
Dmitry S Karlov1, Nadezhda S Temnyakova2, Dmitry A Vasilenko2, Oleg I Barygin3, Mikhail Y Dron3, Arseniy S Zhigulin3, Elena B Averina2, Yuri K Grishin2, Vladimir V Grigoriev4, Alexey V Gabrel'yan4, Viktor A Aniol5, Natalia V Gulyaeva5, Sergey V Osipenko1, Yury I Kostyukevich1, Vladimir A Palyulin2, Petr A Popov1, Maxim V Fedorov1,6.
Abstract
NMDA (N-methyl-d-aspartate) receptor antagonists are promising tools for the treatment of a wide variety of central nervous system impairments including major depressive disorder. We present here the activity optimization process of a biphenyl-based NMDA negative allosteric modulator (NAM) guided by free energy calculations, which led to a 100 times activity improvement (IC50 = 50 nM) compared to a hit compound identified in virtual screening. Preliminary calculation results suggest a low affinity for the human ether-a-go-go-related gene ion channel (hERG), a high affinity for which was earlier one of the main obstacles for the development of first-generation NMDA-receptor negative allosteric modulators. The docking study and the molecular dynamics calculations suggest a completely different binding mode (ifenprodil-like) compared to another biaryl-based NMDA NAM EVT-101. This journal is © The Royal Society of Chemistry.Entities:
Year: 2022 PMID: 35923717 PMCID: PMC9298482 DOI: 10.1039/d2md00001f
Source DB: PubMed Journal: RSC Med Chem ISSN: 2632-8682